Back to search resultsSummaryRMgm-4707
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31958569 Reference 2 (PMID number) : 34604117 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Niikura M, Kobayashi F |
Name Group/Department | Department of Environmental Science, School of Life and Environmental Science |
Name Institute | Azabu University |
City | Kanagawa |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4707 |
Principal name | Δgbp2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | In the first paper: Reduced growth/multiplication of asexual blood stages. Blood stage infections induce experimental cerebral malaria (ECM) in C57Bl6 mice. In the second paper: normal (wild type) growth of asexual blood stages. |
Gametocyte/Gamete | (Strongly) reduced numbers of male and female gametocytes |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1205000 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1006800 | ||||||||||||||||||||||||
Gene product | single-strand telomeric DNA-binding protein GBP2, putative | ||||||||||||||||||||||||
Gene product: Alternative name | GBP2, G-strand binding protein 2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | unknown | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The gene-targeting vector for GBP2, gbp2 (PBANKA_120500), was prepared by PCR. Briefly, the 5'and 3' flanking regions of the gbp2 open reading frame (ORF) were amplified by PCR. The PCR products were annealed to either side of the red fluorescent protein gene (mCherry)-hdhfr-expressing cassette and amplified by PCR using gene-specific primers | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |